Meeting
2023 ASCO Annual Meeting
RINGSIDE phase 2/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results.
Authors
Mrinal M. Gounder
Memorial Sloan Kettering Cancer Center, New York, NY
Mrinal M. Gounder , Robin Lewis Jones , Rashmi Chugh , Mark Agulnik , Arun S. Singh , Brian Andrew Van Tine , Vladimir Andelkovic , Edwin Choy , Jeremy Howard Lewin , Ravin Ratan , Gary B. Gordon , Jonathan Yovell , Andres A. Gutierrez , Bernd Kasper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04871282
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11515)
DOI
10.1200/JCO.2023.41.16_suppl.11515
Abstract #
11515
Poster Bd #
449
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
First Author: Sebastian Grosicki
Poster
2022 ASCO Genitourinary Cancers Symposium
Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study.
First Author: Jose De La Cerda
Poster
2020 ASCO Virtual Scientific Program
RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
First Author: Luis G. Paz-Ares
Poster
2016 ASCO Annual Meeting
A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).
First Author: Antonio Llombart-Cussac